
What We’re Reading: Priority Review for Merck Pneumococcal Vaccine; Bluebird Bio Splits Into 2 Companies; Novel Coronavirus Variant in Japan
FDA accepts for priority review a Biologics License Application for V114, Merck's investigational 15-valent pneumococcal conjugate vaccine; bluebird bio will be split into 2 publicly traded drug companies; a new variant of coronavirus is reported in Japan.
FDA Accepts BLA for Merck’s Pneumococcal Conjugate Vaccine
Today, Merck
Biotech Company Bluebird Will Split Into 2 Companies
According to the
Novel Coronavirus Variant Found in Japan
Yesterday, the World Health Organization (WHO) said that a new variant of the novel coronavirus was reported in Japan and found in 4 people arriving from Brazil, although details of whether the variant is more infectious, like that found in the
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.